ABT vs ENVX · P/E 25, rev $44.33B vs rev $16.6M
Abbott Laboratories (ABT) versus Enovix Corp (ENVX) — a side-by-side from cached financials, not a winner call.
Abbott Laboratories (ABT) is a medical devices company listed on NYSE.
Enovix Corp (ENVX) is a electrical equipment & parts company listed on US.
Latest reported ABT revenue for 2025-12-31 was $44.33B. Net income was $6.52B. Revenue was up 5.7% from 2024-12-31 to 2025-12-31. ABT currently screens at market cap $154.15B and trailing P/E 24.8.
Latest reported ENVX revenue for 2026-07-05 was $16.6M. Net income was -$81.3M. ENVX currently screens at market cap $2.79B.
ABT currently screens at market cap $154.15B and trailing P/E 24.8. ENVX currently screens at market cap $2.79B.
Not investment advice. Open the ABT and ENVX stock pages for the full models.
Not investment advice.